Janneke E. Jaspers

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Sven Rottenberg, Janneke E. Jaspers, Ariena Kersbergen et al. · Proceedings of the National Academy of Sciences · 2008 · 949 citations · Full text

Medicine, Oncology, Pharmacology +16

REV7 counteracts DNA double-strand break resection and affects PARP inhibition

Guotai Xu, J. Ross Chapman, Inger Brandsma et al. · Nature · 2015 · 592 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +14

Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i> -Mutated Mouse Mammary Tumors

Janneke E. Jaspers, Ariena Kersbergen, Ute Boon et al. · Cancer Discovery · 2012 · 515 citations · Full text

Medicine, Oncology, Pharmacology +17

Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study

Hans J. Hammers, Henk M.W. Verheul, Brenda Salumbides et al. · Molecular Cancer Therapeutics · 2010 · 171 citations · Full text

Medicine, Oncology, Pharmacology +17

IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models

Janneke E. Jaspers, Jonathan F. Khan, William D. Godfrey et al. · Journal of Clinical Investigation · 2023 · 170 citations · Full text

Life Sciences, Immunology, Oncology +17